Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
herpes
Biotech
Alfasigma pens €125M deal for injectable form of HSV treatment
Italian pharma Alfasigma penned a 125 million euro deal for the rights to an injectable form of an HSV encephalitis treatment.
James Waldron
Jan 15, 2026 6:45am
Gilead pays $35M to license pair of HSV assets from Assembly Bio
Dec 22, 2025 10:35am
Gilead pays $100M for first dibs on all Assembly Bio assets
Oct 17, 2023 7:00am
AiCuris sharpens strategic focus of infectious disease pipeline
Jul 6, 2023 11:12am
BioNTech lines up 5 infectious disease trials for 2023
Nov 7, 2022 6:57am
New antiviral class could halt treatment-resistant viruses
May 16, 2022 3:10pm
